Roche's Hemlibra gets speedy FDA review for wider use

ZURICH (Reuters) - Roche's hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company's plans to muscle in on turf dominated by rivals including Shire.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news